Senseonics Launches First Commercial Integration of One-Year CGM with Automated Insulin Delivery System
核心洞察
Senseonics Holdings (搜索) has successfully launched the first commercial patients using its Eversense 365 (搜索) continuous glucose monitor integrated with Sequel MedTech (搜索)'s twiist (搜索) automated insulin delivery system.
The integration represents the first time a one-year implantable CGM has been paired with an AID platform, offering patients reduced sensor changes and automated real-time insulin adjustments.
Broad availability of the combined system is expected by March 2026, with the company's stock gaining 8% following the announcement.
Senseonics Holdings (搜索), Inc. (NASDAQ: SENS) has achieved a significant commercialization milestone with the launch of its Eversense 365 (搜索) continuous glucose monitor (CGM) integrated with Sequel MedTech (搜索)'s twiist (搜索) automated insulin delivery (AID) system. The company announced that the first commercial patients have begun using the combined solution, marking the first time a one-year, implantable CGM has been paired with an AID platform.
Revolutionary Integration in Diabetes Management
The commercial launch provides people with type 1 diabetes a new level of flexibility and personalization in their diabetes management. Pairing twiist (搜索) with Senseonics' Eversense 365 (搜索) represents a major milestone in holistic, long-term diabetes management by reducing the need for regular sensor changes and re-pairing, while maintaining exceptional accuracy.
As the only implantable CGM available, Eversense 365 (搜索) offers patients a truly differentiated CGM experience, providing one year of exceptionally accurate monitoring with minimal interruptions. The system's unique approach allows people to overcome common frustrations and interruptions experienced with traditional, short-term CGMs, enabling patients to focus on managing their diabetes rather than their CGM.
Advanced Technology Features
The twiist (搜索) AID system incorporates several innovative features that distinguish it from existing automated insulin delivery systems. The system is the first and only to use iiSure technology to directly measure the volume of insulin delivered, helping ensure accuracy and occlusion detection up to nine times faster than other AID systems. Powered by the twiist Loop algorithm, the system automatically adjusts insulin delivery based on real-time sensor readings and predicted glucose levels to reduce the burden of managing diabetes.
Eversense 365 (搜索)'s implantable design supports uninterrupted glucose monitoring for up to one year, addressing common challenges associated with frequent sensor changes, adhesive wear, and connectivity disruptions seen in short-duration CGMs. The integration is intended to provide a more seamless, personalized diabetes management experience, particularly for patients requiring intensive insulin therapy.
Leadership Perspectives
"While our technologies are unique, our goal is the same - to improve lives and reduce complexity for patients living with diabetes," said Tim Goodnow, President and CEO of Senseonics. "We are proud to partner with Sequel and provide the necessary glucose monitoring data to power the twiist (搜索) Loop algorithm, which enables real-time insulin delivery decisions through the twiist pump. Patients and providers want reliable, long-term automated glucose readings and we've taken a major step forward in simplifying and personalizing diabetes management."
Alan Lotvin, CEO of Sequel MedTech (搜索), emphasized the personalized approach: "Diabetes management is deeply personal, and no single approach works for everyone. Our focus on personalization means Sequel is committed to creating choice for people living with diabetes; integration with the Eversense CGM is an important step in this journey, enabling more people to experience the precision and confidence that twiist (搜索) AID system brings to diabetes management."
Market Impact and Availability
Following the announcement, shares of Senseonics gained 8% in trading. However, over the last six-month period, SENS shares have declined 28.8% compared with the industry's 10.5% decline, while the S&P 500 increased 13.2% in the same timeframe. The company currently has a market capitalization of $269.3 million.
Broad availability of twiist (搜索) with Eversense 365 (搜索) is expected by March 2026. The integration is expected to benefit Senseonics' business long-term by expanding the addressable market for Eversense 365 and improving its competitiveness against traditional CGM players.
Financial Performance Context
Senseonics delivered strong improvement in its third-quarter 2025 financial performance, with total revenue rising to $8.1 million from $4.3 million in the prior-year period, driven by 160% new patient growth in the United States. U.S. revenue nearly tripled year over year to $6.4 million, reflecting improving commercial traction. The company reported a gross profit of $3.5 million in the quarter against a gross loss of $4.1 million a year ago, highlighting meaningful progress in cost structure and operating efficiency.
Market Outlook
According to Grand View Research, the global blood glucose monitoring devices market size was estimated at $15.53 billion in 2025 and is projected to reach $30.18 billion by 2033, expanding at a CAGR of 8.8% from 2026 to 2033. The market is primarily influenced by the growing prevalence of diabetes and the increasing elderly population susceptible to diabetes-related conditions.